Company / Cash & Equivalents
PRECISION BIOSCIENCES INC Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$110.8M
FY2025
5-year range
$85.9M / $189.6M
FY2021-FY2025
Trend
+29.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $111M.
Based on SEC 10-K filings.
$111M in FY2025 with a 5-year CAGR of +4.3%.
Declined from $117M to $111M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -16.4%
- 5-Year CAGR
- +4.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +4.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 29.0% year-over-year.
- Peak cash & equivalents was recorded in FY2022.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.67 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $110.8M | +29.0% |
| FY2024 | $85.9M | -26.4% |
| FY2023 | $116.7M | -38.5% |
| FY2022 | $189.6M | +32.0% |
| FY2021 | $143.7M | +60.0% |
| FY2020 | $89.8M | -50.4% |
| FY2019 | $180.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026